Medscape Transplantation Podcast

Drs Lisa VanWagner and Kathleen Corey examine how MASLD should shape cardiovascular risk assessment, statin use, and treatment decisions.

Dr Benjamin Levy III reviews how to recognize, evaluate, and manage colitis and other GI complications that can arise with immune checkpoint inhibitors.

Listener feedback on the nonobstructive HCM trials, AI-enhanced visits, timing of non-culprit PCI in STEMI, new tricuspid valve intervention, and EP at a crossroads are the topics John Mandrola, MD, discusses in this week’s podcast.

A preview of ACR 2026 updates in SLE and lupus nephritis, spanning emerging therapies, kidney biopsy findings, cardiovascular risk management, and individualized dosing.

Key findings from HFSA 2026, including emerging diagnostic imaging, health status and cardiac biomarker findings, and initiatives to improve disease recognition and management.

Dr Jeffrey Turner spotlights advances in CKD therapy implementation, emerging treatments, xenotransplantation, and the responsible use of AI in nephrology.

Dr Mazen Noureddin explains how PCPs can identify MASH patients with fibrosis who may benefit from liver-directed therapy, while maintaining lifestyle and metabolic care.

Two new AGA updates reshape how clinicians test for, treat, and prevent recurrent C difficile, including tailored guidance for patients with IBD.

Drs Alexander and Urey walk through stabilizers vs silencers, pivotal trial data, and practical first line choices to help you select the right ATTR CM therapy for each patient.

When fatty liver appears incidentally on imaging, "just lose weight" isn't enough. Dr Brandman explains how to use FIB-4, FibroScan, and ELF to triage who needs referral and who doesn't.

Dr Maurie Markman discusses why modifying cancer diets without RCT data poses major risks, highlighting a trial halted due to a 10% spike in serious infections.

With a 34-state Cyclospora outbreak driving GI visits, Dr Levy breaks down diagnosis, testing pitfalls, and treatment clinicians need to know.

From missed red flags to insurance denials, the barriers to ATTR-CM care are multi-level. Drs Alexander and Pino-Moreno break down what’s failing and how to fix it.

Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Dr Yash Varma, a chief cardiology fellow, asks Dr Ileana Piña for her insights on when a patient with heart failure should be referred for advanced therapies.

Chief Cardiology fellow Yash Varma asks HF expert Ileana Piña for tips on when patients are stable to discharge on guideline-directed medical therapy and if it’s ever ok to de-escalate.

In this DDW 2026 update, Dr David Johnson reviews key advances in cirrhosis care, GLP-1 benefits, earlier HCC detection, colorectal cancer risks, and IL-23-targeted IBD therapies.

Chief fellow Yash Varma asks heart failure expert Ileana Piña for her tips and tricks in managing patients admitted with acute decompensated heart failure.

ATTR-CM is the zebra hiding among the horses. AI may finally be the tool that finds it. Experts Drs Kevin Alexander and Lily Stern explore what's working, what's not, and what comes next.